Hold Rivaroxaban 1 Day Before D&C
For an adult female with normal renal function undergoing dilation and curettage (D&C), hold rivaroxaban for 1 day (24 hours) before the procedure. This means skipping one dose if taken once daily, with the last dose taken 2 days before surgery 1.
Rationale Based on Bleeding Risk Classification
D&C is classified as a low-to-moderate bleeding risk procedure. The 2022 American College of Chest Physicians guidelines explicitly recommend 1:
- 1 day off before low-to-moderate-bleed-risk procedures when creatinine clearance ≥ 50 mL/min
- 2 days off before high-bleed-risk procedures
This recommendation is based on rivaroxaban's half-life of 8-9 hours 2. Holding for 1 day (approximately 24-36 hours from last dose to procedure) allows 2-3 drug half-lives to elapse, resulting in acceptable residual anticoagulant effect for lower-risk procedures 2.
Pharmacokinetic Support
The FDA label confirms rivaroxaban has a terminal elimination half-life of 5-9 hours in healthy adults aged 20-45 years 3. With normal renal function, a 24-hour hold achieves sufficient drug clearance for procedures without high bleeding risk.
Key Implementation Points
- Day of procedure: Do not take rivaroxaban on the day of surgery 1
- No bridging needed: The rapid offset of rivaroxaban eliminates the need for heparin bridging 1
- Resumption timing: Restart rivaroxaban at least 24 hours after the procedure once hemostasis is established 1, 2
Important Caveats
If the patient has impaired renal function (CrCl 30-50 mL/min), the same 1-day hold applies for low-to-moderate bleeding risk procedures 2. However, if D&C is considered higher risk in a specific clinical context (e.g., anticipated difficult hemostasis, coagulopathy), extend to 2 days off 1.
Do not extend the hold unnecessarily - longer interruption periods increase thrombotic risk without additional bleeding benefit for standard D&C procedures. The 2024 AHA/ACC guidelines support this streamlined approach, showing low rates of major bleeding with standardized 1-day interruption protocols for moderate-risk procedures 4.